Cyramza
Eli Lilly names Ilya Yuffa as executive vice president and president, Lilly Global Markets
Patrik Jonsson, executive vice president and president, Lilly International, will retire at the end of 2026
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients
Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal
The deal focuses on addressing critical unmet medical needs
FDA approves Priovant’s Lisraya for dermatomyositis
This is the first oral drug treatment for this rare disease in adults
AstraZenca’s Etcamah combination therapy given FDA Accelerated Approval for breast cancer
The approval was based on phase 3 trial results showing a 56% risk reduction in disease progression
Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine approved by US FDA
The 2026-2027 vaccine targets the XFG variant to more closely match current variants
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
FDA grants Fast Track status for peanut allergy immunotherapy
The treatment uses peptides designed to retrain the immune system to tolerate peanuts
Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes
The UK is the first country in Europe to authorise the oral medication
Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer
Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually